Origin Agritech's Pioneering Hi3 Gene Editing Technology Awarded as Top 10 Major Progress in Chinese Agricultural Science for 2025, as Company Advances Commercialization

Origin Agritech's Pioneering Hi3 Gene Editing Technology Awarded as Top 10 Major Progress in Chinese Agricultural Science for 2025, as Company Advances Commercialization

BEIJING, Dec. 2, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that its pioneering corn haploid induction line Hi3 gene editing technology has...

Apacer Introduces ECO Series and AS714 Portable SSD with Next-Gen Creative Performance

Apacer Introduces ECO Series and AS714 Portable SSD with Next-Gen Creative Performance

TAIPEI, Dec. 2, 2025 /PRNewswire/ -- In response to global sustainability trends, Apacer Technology Inc. has unveiled its new ECO Series portable storage products made from fully recycled plastic materials, alongside the AS714 Portable SSD, which...

Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection

Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection

BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The Faculty of Medicine , Chulalongkorn University, in collaboration with the Faculty of Engineering, has developed "Deep GI," an artificial intelligence (AI) innovation designed to assist doctors in detecting...

Suchang Accelerates Global Expansion With Dog Food Made From Jeju Citrus By-products

Suchang Accelerates Global Expansion With Dog Food Made From Jeju Citrus By-products

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Suchang a Korean manufacturer specializing in over 150 types of natural bio-based ingredients and overseas distribution consulting, announced that it has successfully developed a new dog food product...

Tsinghua University Releases the First University-Wide Framework Governing AI in Teaching and Research

Tsinghua University Releases the First University-Wide Framework Governing AI in Teaching and Research

BEIJING, Dec. 1, 2025 /PRNewswire/ -- Tsinghua University recently released the "Tsinghua University Guiding Principles for the Application of Artificial Intelligence in Education" (Guiding Principles), the institution's first comprehensive,...

Helios 50 MW BESS achieves commercial operations in Hokkaido, Japan

Helios 50 MW BESS achieves commercial operations in Hokkaido, Japan

TOKYO, Dec. 1, 2025 /PRNewswire/ -- Manoa Energy ("Manoa" or the "Company") today announced the start of commercial operations for the Helios 50MW Battery Energy Storage System ("BESS") in Sapporo City, Hokkaido, Japan. The Helios 50MW / 104 MWh...

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9 - , 30 - , and 60-fold higher than semaglutide, tirzepatide, and retatrutide in...

JA Solar Releases Industry's First Desert-Gobi-Wasteland PV Solution White Paper

JA Solar Releases Industry's First Desert-Gobi-Wasteland PV Solution White Paper

BEIJING, Nov. 29, 2025 /PRNewswire/ -- JA Solar, a trusted global partner in green energy, has released the industry's first Desert-Gobi-Wasteland PV Solution White Paper during its sideline event at the 21st China SoG Silicon and PV Power...

The Unseen Itch: Over Half of Singaporeans With Eczema Struggle With Sleep Loss, Shame and Social Withdrawal Due to Itch

The Unseen Itch: Over Half of Singaporeans With Eczema Struggle With Sleep Loss, Shame and Social Withdrawal Due to Itch

A recently concluded survey by Medical Channel Asia sheds light on the debilitating effects of constant itch caused by eczema. SINGAPORE, Nov. 25, 2025 /PRNewswire/ -- A new ground-up survey "The Unseen Itch: How Eczema Disrupts Daily Life in...

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 20
  • menu
    menu